Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1365-1382

  Vidal, Francesc ^a   Domingo, Pere ^b   Viladés, Consuelo ^a   Peraire, Joaquim ^a   Arnedo, Mireia ^c   Alcam, José ^d   Leal, Manuel ^e   Villarroya, Francesc ^c   Gatell, Josep Ma ^c  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Antiretroviral therapy; HIV infection; Lipodystrophy; Pharmacogenetics

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; ARYLDIALKYLPHOSPHATASE 1; BETA 3 ADRENERGIC RECEPTOR; CYTOKINE; DIDANOSINE; EFAVIRENZ; HLA B ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LAMIN A; LAMIVUDINE PLUS ZIDOVUDINE; LEPTIN; MITOCHONDRIAL DNA; NELFINAVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAVUDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TOLL LIKE RECEPTOR 4; ZIDOVUDINE;

ADIPOCYTE; DRUG METABOLISM; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MITOCHONDRION; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; GENETIC PREDISPOSITION TO DISEASE; HIV; HIV INFECTIONS; HUMANS; LIPODYSTROPHY;

EID: 80054751309     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.621941     Document Type: Review

References (108)

1. Gazzard B. Antiretroviral therapy for HIV: medical miracles do happen. Lancet 2005;366:346-7 (Pubitemid 41073943)
2. Lejeune M, Miro JM, De Lazzari E, et al. Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. Clin Infect Dis 2011;52:662-70
3. Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of. Toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000;355:2217-28
4. Bernaldo L, de Quiros JC, Miro JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001;344:159-67 (Pubitemid 32064136)
5. Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009;1791:507-13
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8 (Pubitemid 28190689)
7. Caron M, Boccara F, Lagathu C, et al. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr Pharm Des 2010;16:3352-60
8. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005;26:88-93 (Pubitemid 40170171)
9. Moyle G, Moutschen M, Martinez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010;12:3-14
10. Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV infection and antiretroviral treatment. Biochim Biophys Acta 2010;1801:392-9
11. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-35 (Pubitemid 36293626)
12. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70 (Pubitemid 28121175)
13. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998;351:71-5
14. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8 (Pubitemid 32179612)
15. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1657-67
16. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16 (Pubitemid 30459502)
17. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16:2447-54 (Pubitemid 35471693)
18. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation on the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 2003;17:971-9 (Pubitemid 36549708)
19. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006;11:729-40 (Pubitemid 44497168)
20. Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010;16:218-29
21. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infect Genet Evol 2007;7:333-42 (Pubitemid 46187499)
22. Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther 2007;12:999-1013 (Pubitemid 350114980)
23. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005;437:1299-320
24. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005;366:1315-23 (Pubitemid 41416588)
25. Arnedo M, Taffe P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007;17:755-64 (Pubitemid 47263070)
26. Colhoun HM, McKeigue PM, Davey SG. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72 (Pubitemid 36331853)
27. Freimer NB, Sabatti C. Guidelines for association studies in Human Molecular Genetics. Hum Mol Genet 2005;14:2481-3 (Pubitemid 41236060)
28. Cote H, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20 (Pubitemid 34984654)
29. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-9 (Pubitemid 32939241)
30. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-38 (Pubitemid 36819847)
31. McComsey GA, Libutti DE, O'Riordan M, et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther 2008;13:715-22
32. Walker UA, Bickel M, Lutke-Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002;29:117-21 (Pubitemid 34164881)
33. de Mendoza C, Sanchez-Conde M, Ribera E, et al. Could be mitochondrial DNA quantitation a surrogate marker for drug mitochondrial toxicity. AIDS Rev 2004;6:169-80 (Pubitemid 39599987)
34. Kim MJ, Jardel C, Barthelemy C, et al. Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus related lipodystrophy. Antimicrob Agents Chemother 2008;52:1670-6 (Pubitemid 351614659)
35. McComsey G, Tan DJ, Lederman M, et al. Analysis of mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002;16:513-18 (Pubitemid 34218845)
36. Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial mutations in human immunodeficientcy virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet 2003;72:549-60 (Pubitemid 36255954)
37. Ortiz M, Poloni ES, Furrer H, et al. No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. J Infect Dis 2011;201:620-4
38. Nasi M, Guaraldi G, Orlando G, et al. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy. Clin Infect Dis 2008;47:962-8
39. Hulgan T, Tebas P, Canter JA, et al. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis 2008;197:858-66 (Pubitemid 351417009)
40. Hendrikson SL, Kingsley LA, Ruiz-Pesini E, et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009;51:111-16
41. Hulgan T, Haubrich R, Riddler S, et al. European mitochondrial DNA haplogroups and metabolic changes dring antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 2011;25:37-47
42. Chiappini F, Teicher E, Saffroy R, et al. Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. Curr HIV Res 2009;7:244-53
43. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett 2008;582:117-31
44. Domingo P, Vidal F, Domingo JC, et al. Tumor necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005;35:771-80 (Pubitemid 41783595)
45. Ledru E, Christeff N, Patey O, et al. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-8 (Pubitemid 30321172)
46. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286:E261-71 (Pubitemid 38140318)
47. Lindegaard B, Eg Hansen AB, Gerstoft J, Pedersen BK. High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy. J Acquir Immune Defic Syndr 2004;36:588-93 (Pubitemid 38544507)
48. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8(Suppl 2):S2
49. He G, Andersen O, Haugaard SB, et al. Plasminogen activator inhibitor type I (PAI-I) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest 2005;35:583-90 (Pubitemid 41243302)
50. Jones SP, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine-and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005;40:565-72 (Pubitemid 41669161)
51. Vigouroux C, Maachi C, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-11 (Pubitemid 36900551)
52. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003;17:1753-62 (Pubitemid 37000093)
53. Huising MO, Stet RJM, Savelkoul HFJ, Verburg-van Kemenade BML. The molecular evolution of the interleukin-1 family of cytokines; IL-18 in telest fish. Dev Comp Immunol 2004;28:395-413 (Pubitemid 38177444)
54. Lindegaard B, Eg Hansen AB, Pilegaard H, et al. Adipose tissue expression of IL-18 and HIV-associated lipodystrophy. AIDS 2004;18:1956-8 (Pubitemid 39313213)
55. Iannello A, Samarani S, Debbeche O, et al. Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions. Curr HIV Res 2010;8:147-64
56. Maher B, Alfirevic A, Vilar FJ, et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002;16:2013-18 (Pubitemid 35205264)
57. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005;191:1419-26 (Pubitemid 40563352)
58. Asensi V, Rego C, Montes AH, et al. IL-1beta (+3954C/T) polymorphism could protect HIV-infected patients on HAART against the lipodystrophic syndrome. Genet Med 2008;10:215-23
59. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003;17:121-3 (Pubitemid 36106307)
60. Veloso S, Olona M, Peraire J, et al. No relationship between TNF-alpha genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis. AIDS Res Hum Retroviruses 2011;27:143-52
61. Saumoy M, Lopez-Dupla M, Veloso S, et al. A study of the IL-6 system in HIV-1-infected patients with combination antiretroviral therapy-related fat redistribution syndromes. AIDS 2008;22:893-6 (Pubitemid 351563839)
62. Castelar L, Silva MM, Castell EC, et al. Interleukin-18 and interferon-gamma polymorphisms in Brazilian human immunodeficiency virus-1-infected patients presenting with lipodystrophy syndrome. Tissue Antigens 2010;76:126-30
63. Lago F, Gomez R, Gomez-Reino JJ, et al. Adipokines as novel modulators of lipid metabolism. Trends Biochem Sci 2009;34:500-11
64. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: clinical applications. Ann Intern Med 2010;152:93-100
65. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 2007;40:55-67 (Pubitemid 47305235)
66. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2005;255:439-47 (Pubitemid 38446357)
67. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS 2007;21:895-904 (Pubitemid 46684320)
68. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12 (Pubitemid 32151228)
69. Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008;22:1561-8
70. Escote X, Miranda M, Veloso S, et al. Lypodystrophy and insulin resistance in HIV-1-infected patients treated with antiretroviral drugs: implication of resistin. J Acquir Immune Defic Syndr 2011;57:16-23
71. Trinca JR, Sprinz E, Lazzaretti RK, et al. SNPs in the APM1 gene promoter are associated with adiponectin levels in HIV-infected individuals receiving HAART. J Acquir Immune Defic Syndr 2010;55:299-305
72. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004;350:1220-34 (Pubitemid 38339366)
73. Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission: a new syndrome. Q J Med 1974;43:33-48
74. Garg A, Peshock RM, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 1999;84:170-4 (Pubitemid 29036696)
75. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994;135:798-800 (Pubitemid 24241266)
76. Chavey C, Mari B, Monthouel MN, et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003;278:11888-96 (Pubitemid 36800160)
77. Araujo-Vilar D, Lattanzi G, Gonzalez-Mendez B, et al. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy. J Med Genet 2009;46:40-8
78. Bonnet E, Bernard J, Fauvel J, et al. Association of APOC3 polymorphisms with both dyslipemia and lipoatrophy in HAART-receiving patients. AIDS Res Hum Retroviruses 2008;24:169-71 (Pubitemid 351282094)
79. Vonkelman HE, Napel CHH, Oeveren-Dybicz AM, Vermes I. Beta3-adrenergic receptor polymorphism and the antiretroviral therapy-related lipodystrophy. AIDS 2000;14:1463-4 (Pubitemid 30459527)
80. Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000;24:153-6 (Pubitemid 30094715)
81. Lloyd DJ, Trembath RC, Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet 2002;11:769-77 (Pubitemid 34428644)
82. Miranda M, Chacon MR, Vidal F, et al. LMNA messenger RNA expression in highly active antiretroviral therapy-treated HIV-positive patients. J Acquir Immune Defic Syndr 2007;46:384-9 (Pubitemid 350098687)
83. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maduration and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003;17:2437-44 (Pubitemid 38393315)
84. Behrens GM, Lloyd D, Schmidt HH, et al. Lessons from lipdystrophy: LMNA, encoding lamin A/C in HIV therapy-associated lipodystrophy. AIDS 2000;14:1854-5
85. Domingo P, Baiget M, Arroyo JA, et al. Absence of mutations in exon 8 of the LMNA gene in combination antiretroviral therapy-associated partial lipodystrophy. J Acquir Immune Defic Syndr 2002;30:457-8 (Pubitemid 34857321)
86. Behrens GM, Genschel J, Schmidt RE, Schmidt HH. Lack of mutations in LMNA, its promoter region, and in the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy. Eur J Med Res 2003;30:221-5
87. Ahmed W, Ziouzenkova O, Brown J, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007;262:184-98 (Pubitemid 47087629)
88. Agostini M, Schoenmakers E, Mitchell C, et al. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab 2006;4:303-11 (Pubitemid 44430916)
89. Saumoy M, Veloso S, Alonso-Villaverde C, et al. PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. Curr HIV Res 2009;7:533-40
90. Zanone Poma B, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008;22:1769-78
91. Montes AH, Valle-Garay E, Suarez-Zarracina T, et al. The MMP1 (-16071G/2G) single nucleotide polymorphism associates with the HAART-related lipodystrophic syndrome. AIDS 2010;24:2499-506
92. Pushpakom SP, Owen A, Vilar FJ, et al. Adipogenic gene variants in patients with HIV-associated lipodystrophy. Pharmacogenet Genomics 2011;21:76-83
93. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-405 (Pubitemid 34507951)
94. Nolan D, Hammond E, James I, et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003;8:617-26 (Pubitemid 38057108)
95. Domingo P, Cabeza MC, Pruvost A, et al. Association of thymidylate synthase gene polymorphisms with Stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother 2011;55:1428-35
96. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, et al. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin Infect Dis 2010;50:597-604
97. Parra S, Marsillach J, Aragones G, et al. Association of Paraoxonase-1 gene haplotypes with the immunologic outcome and the metabolic disturbances and atherosclerosis in HIV-infected patients. J Infect Dis 2010;201:627-34
98. Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006;20:1503-13 (Pubitemid 44100211)
99. Torre D, Pugliese A, Speranza F. Role of nitric oxide in HIV-1 infection: friend or foe? Lancet Infect Dis 2002;2:273-80 (Pubitemid 34464738)
100. MacMicking JD, North RJ, la Course R, et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997;94:5243-8 (Pubitemid 27214768)
101. Asensi V, Montes AH, Valle E, et al. The NOS3 (27bp repeat, intron 4) polymorphism is associated with susceptibility to osteomyelitis. Nitric Oxide 2007;16:44-53 (Pubitemid 44820883)
102. Carty M, Bowie AG. Recent insights into the role of Toll-like receptors in viral infection. Clin Exp Immunol 2010;161:397-406
103. Bafica A, Scanga CA, Schito M, et al. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J Immunol 2004;172:7229-34 (Pubitemid 38747580)
104. Bochud PY, Hersberger M, Taffe P, et al. Polymorphism in Toll-like receptor 9 influences the clinical course of HIV.1 infection. AIDS 2007;10:441-6
105. Lorenz F, Mira JP, Kornish KL, et al. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2002;68:6398-401
106. Lorenz F, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR receptor in patients with Gram-negative septic shock. Arch Intern Med 2002;162:1028-32 (Pubitemid 34492532)
107. Montes AH, Asensi V, Alvarez V, et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and hematogenous osteomyelitis. Clin Exp Immunol 2006;143:404-13
108. Konner AC, Bruning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab 2011;22:16-23